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Differentiated thyroid cancer arising from thyroid follicular epithelial cells is the most
frequent endocrine malignancy, and skin metastases are very rare. We describe a case
of a 70-year-old women with a history of an indeterminate thyroid nodule on cytology.
A painless, erythematous skin nodule of about 7mm diameter was removed from the
scalp and diagnosed as a metastasis from thyroid cancer. After total thyroidectomy, a
histological diagnosis of follicular thyroid cancer was made. Two cycles of radioactive
iodine were performed. Both the follicular thyroid carcinoma (FTC) and the metastasis
were investigated for the presence of BRAF/RAS and TERT promoter mutations.
The results showed that the cutaneous metastasis was BRAF wild-type and TERT
promoter-mutated (position g.1,295,228 C>T); in contrast, the primary thyroid lesion
was negative for both molecular markers.
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INTRODUCTION
The most frequent endocrine malignancy is differentiated thyroid carcinoma (DTC). Regional
cervical lymph nodes are the most common sites of local metastases, while lung and bone are
the most usual sites of distant metastases. Skin metastases are very rare, the scalp being the most
frequent site (1). We report the case of a woman who presented a single skin lesion as the first sign
of DTC, in which the metastatic site, but not the primary tissue, displayed TERT mutation.
CASE REPORT
A 70-year-old women was referred to an endocrinology center owing to multinodular goiter.
She had a family history of benign nodular thyroid pathology. Thyroid ultrasound revealed a
multinodular goiter with a 20mm hypoechoic nodule in the right lobe and a 25mm hypoechoic
nodule with microcalcifications in the left lobe. Her thyroid function was unknown, but oral levo-
thyroxine therapy was started in November 2014. Fine-needle cytology (FNAC) on the right nodule
confirmed the benign nature of the lesion: THY 2 according to the second edition of the British
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Thyroid Association (BTA) classification (2). FNAC on the left
nodule showed an indeterminate lesion (THY 3 according to
BTA 2007); 3 months later, a new cytological evaluation was
performed. This second FNAC confirmed the indeterminate
cytology (THY 3A according to the third BTA classification, BTA
2014) (3). Analysis of BRAF V600E mutation of the cytological
specimens revealed a wild-type genotype. Thus, the patient was
advised to undergo ultrasound follow-up, but refused. After 2
years, the patient noticed a painless, erythematous skin nodule of
about 7mm diameter on the scalp. The lesion was removed and
the histological diagnosis suggested a thyroidal origin; the nodule
was composed of epithelial cells arranged in follicular structures
which contained amorphous material resembling thyroid colloid
(Figure 1A). On immunohistochemical staining, neoplastic cells
showed expression of TTF-1 (Figure 1B), Cytokeratin 7, and
Thyroglobulin (Tg); thus, a diagnosis of probable metastasis from
a follicular thyroid carcinoma (FTC) wasmade.When the patient
was referred to our clinic (November 2017), her BMI was high
(43 kg/m2), her thyroid function was normal (TSH 2.33 mIU/L)
with high levels of Tg (6,752 µg/L; normal range 3.5–77 µg/L),
calcitonin was <1.0 ng/L and autoimmunity was negative. A
thyroid ultrasound scan (US) revealed a hypoechoic right nodule,
with microcalcifications of 20mm, and a hypoechoic left nodule
with microcalcifications of 50mm. After collegial discussion with
the surgeon, nuclear medicine specialist and pathologist, a total-
body PET 18F-FDG scan (with a Siemens somatom sensation
16 biograph, Rome, Italy) was performed; this showed a lung
metastasis with poor 18-FDG uptake (Figure 2A) and a left
thyroid nodule with moderate 18-FDG uptake (Figure 2B).
Total thyroidectomy with central compartment neck
dissection was performed, followed by thyroid ablation with
120 mCi of radioiodine (RAI). To prepare for the ablation, the
patient underwent recombinant human (rh) TSH stimulation
(Thyrogen, four i.m. injections of 1.8mg to the buttock in
the 4 days preceding radioiodine administration). Although
total hormone withdrawal would be the recommended choice,
the use of rhTSH was justified by the patient’s psychological
condition, and the clinicians consented to this therapy (4).
Indeed, a number of literature reports have indicated that both
FIGURE 1 | Skin metastasis. (A) Hematoxylin Eosin staining of histological slides, magnification 4 × 1. *indicates less differentiated areas. (B)
Immunohistochemical staining of TTF-1, magnification 20 × 1.
treatments may have the same type of effect (5, 6). However, the
second course of radioiodine therapy was administered under
total hormone withdrawal, since the patient had, by that time,
acquired enough confidence in the physicians’ advice. After
131I administration, a whole-body x-ray scan was performed
by means of a Philips Forte (Rome, Italy) gamma camera, and
identified some areas of pathological hyperaccumulation of
the tracer: lungs, one vertebra and right hypochondrium. We
then performed a total-body CT scan, which revealed a liver
metastasis and confirmed the lung metastases (Figure 2C).
Histological examinations of thyroid tissue showed a
macroscopic 45mm nodule on the left lobe with the
morphological features of a follicular cancer, and both capsular
and vascular invasion, thus resembling a “widely invasive” FTC
(WHO classification, 2017) in the context of diffuse nodular
hyperplasia (Figure 3 and Supplementary Figure S1).
The second course of RAI treatment, which was administered
at 250mCi under thyroid hormone withdrawal, led to a reduction
in iodine uptake by distant metastases. Before this second
treatment, the patient’s TSH level was 100 U/L, stimulated Tg
was 1,037 µg/L and Tg antibodies were negative. At present,
neck US is negative for disease recurrence. Before the second
ablation, unstimulated Tg was 250 µg/L; it is now 123 µg/L. TSH
is suppressed (0.66 mIU/L) on LT4 therapy (875 µg weekly).
Both the FTC tissue and the skin metastasis were investigated
for the presence of BRAF/RAS and TERT promoter mutations.
While both tissues proved to be BRAF wild-type, the cutaneous
metastasis was TERT promoter-mutated (g.1,295,228 C>T)
(not shown and Figure 4C); in contrast, the primary thyroid
lesion was negative for both molecular markers (not shown
and Figure 4A). Interestingly, a NRAS Gln61Arg mutation
co-occurring with the TERT mutation was found in the
cutaneous metastasis (Figure 4D) but not in the primary
carcinoma (Figure 4B).
DISCUSSION AND CONCLUSIONS
DTChave a good prognosis and>10% of patients develop distant
metastases (8). The Italian consensus on thyroid cancer in Thy
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FIGURE 2 | 18FDG-PET scan showing lung uptake (A) and thyroid uptake (B). Computed Tomography Imaging of lung metastasis (C).
3a lesions suggests that conservative management be considered
in the case of favorable clinical and US criteria, while in Thy 3f
lesions surgery is recommended in most cases (9). The approach
to indeterminate nodules is still debated. It is not clear whether
the subdivision of Thy 3 lesions into Thy 3a (atypical features)
and Thy 3f (follicular lesion) indicates a different oncologic risk,
as suggested in the latest version of the BTA classification3.
Alexander et al. did not observe a real difference in risk, their
rates of malignancy being 24.7.7% in Thy 3, 30.4% in Thy 3a,
and 29.2% in Thy 3f (10). However, the incidence of thyroid
malignancy varied considerably among the four centers involved
in their study (Thy 3f 18–54%). Moreover, in our experience, no
statistically significant difference in the risk of malignancy was
found between Thy 3a (26%) and Thy 3f (14%) nodules (11).
In the literature, some authors have found that the most
common histological type among patients with skin metastases
is FTC (1, 12, 13). In another study, however, Papillary thyroid
carcinoma (PTC) was the most frequent tumor type (41%) in
patients with skin metastases (14). Moreover, on analyzing 16
patients with skin metastases, Erickson et al. found 11 PTC and 5
FTC (15). Indeed, more recently, Cohen et al. observed a 1/1,000
incidence of skin metastases in PTC (16).
The most common metastatic site is consensually the scalp,
as in our case (1, 12–14). Skin metastasis is rarely the first
FIGURE 3 | Thyroid tissue. Hematoxylin Eosin staining of histological slides,
magnification 10 × 1.
manifestation of the tumor, as it was in our patient. In fact,
Somoza et al. reported a similar case, that of a 71-year-old
Caucasian male with a skin metastasis of about 1 cm from a
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FIGURE 4 | 100–200 ng of genomic DNA was extracted from FFPE thyroid tissues (A,B) and cutaneous metastasis (C,D) by using QIAamp DNA FFPE Tissue Kit
(Qiagen, Hilden, Germany) and subjected to TERT promoter amplification (A,C) by PCR as described in Dono et al. (7) and to NRAS exon 3 amplification (B,D) by
PCR using 1.5U Platinum Taq DNA polymerase (Thermo Fisher Scientific, Milan, Italy), 1x buffer, 2mM MgCl2, 200 nM dNTPs, and 30 pmoles of Forward
(5′gattcttacagaaaacaagtgg) and Reverse (5′ taatgctcctagtacctagtgag) primers in a final volume of 50 µl. The amplified PCR products were then treated with ExoSap
(GeHealthcare, Waukesha, USA) as recommended and both strands sequenced by dye terminator cycle sequencing (BigDye Terminator v3.1, Thermo Fisher).
Nucleotide sequence detection was performed on an ABI Prism 3,500 Genetic Analyzer (Thermo Fisher) according to standard protocols. The sequence data were
obtained by Mac Vector software analysis (MacVector Inc., North Carolina, USA).
follicular variant of PTC (17), and Smit et al. found a 79-year-old
Caucasian woman with skin metastases as the first manifestation
of a follicular variant of PTC (18). Jehangir et al. also observed
a Caucasian woman with a history of thyroid nodule who had
rapidly growing skull nodules and a histological diagnosis of
FTC (19), and Shamim et al. published two case reports in
which a skull lesion was the first manifestation (20). In all these
cases, however, the skin lesions were far more advanced than in
our case.
Two recurrent non-coding mutations within the hTERT
promoter region (chr5:1,295,228 G>A and 1,295,250 G>A) were
first described in both familial and sporadic melanomas and later
identified in other tumor types, such as glioblastoma, bladder and
thyroid cancer, as reviewed in reference (21). As these mutations
are present within the promoter, they create new binding sites
for the Etwenty-six (ETS) transcription factor family, thus
constituting an alternative mechanism of genetic activation in
cancer. Indeed, mutated TERT causes inhibition of physiological
telomere shortening, thereby promoting the immortalization
of cancer cells. In thyroid cancer, hTERT mutations are
usually present in follicular-derived thyroid carcinoma and are
associated with more aggressiveness (and advanced forms of
disease) (22). In our case, the patient’s cutaneous metastasis
showed the presence of two concurrent mutations: the 1,295,228
G>A in the TERT promoter and the Gln61Arg in theNRAS gene.
Since expression of members of the ETS family may be induced
by BRAF and RAS mutations, further acquisition of a TERT
mutationmay extend the lifespan of the BRAF/RAS-driven clone,
resulting in the development of a more advanced disease (23).
In our case, both TERT and NRAS mutations were apparently
absent from the primary tumor. However, we cannot exclude that
a minor “aggressive” mutated clone, undetectable bymeans of the
standard genotyping techniques, might have already been present
within the bulk of the primary tumor and that this clone might
have played a role in its progression. This hypothesis seems to
be supported by many studies in which distant metastases have
been correlated with the presence of a TERT promoter mutation,
not only in tissues but also when found in thyroid cytology
specimens (24, 25). Interestingly, the co-occurrence of TERT
promoter mutation with BRAF alteration is already a strong
indicator of the aggressive behavior of disease, as reviewed in
the meta-analysis by Jin et al. (26). Indeed, the co-existence of
TERT promoter and RAS mutations in DTC is already known,
and the synergistic effect of these co-occurring alterations, in
terms of tumorigenesis and aggressiveness, has been described
in several studies (27–29). However, the biological and clinical
significance of this association needs to be further investigated. In
our case, the fact that both mutations were present in the distant
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metastasis corroborates the idea that they both contributed to
the aggressiveness of the tumor. Indeed, in comparison with the
primary tumor, the skin metastasis displayed some areas with less
differentiation, a finding that may correlate with the appearance
of TERT and NRAS mutations (see Figure 3). Of course, it is
difficult to establish which of the TERT and NRAS mutations
occurred earlier, although the hypothesis that the TERTmutation
was a later occurrence is more likely to explain the progression of
the tumor.
In the literature, patients with skull metastases have a
worse prognosis. In our case, early treatment with two doses
of RAI may have made the prognosis more favorable. TERT
promoter mutation, as shown in the literature, is a predictor
of aggressiveness and poorer prognosis (28–30). At the present
time, the patient is still alive, in good condition and totally
asymptomatic. In the meantime, she also underwent a third
course of RAI treatment; her distant metastases have remained
stable (131 Iodine whole-body scan, not shown) and her
unstimulated Tg levels were 277 µg/L.
In the case described, adequate imaging follow-up, as
suggested by Pacini et al. (9), enabled an early diagnosis to be
made and prompt treatment to be undertaken. RAI therapy
remains the most efficacious post-surgical treatment, as shown in
our case by the reduction of distant metastases and thyroglobulin
after the second course of treatment.
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